Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' ZEILLINGER R' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 65 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Tempfer, C; Unfried, G; Zeillinger, R; Hefler, L; Nagele, F; Huber, JC
      Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage

      HUMAN REPRODUCTION
    2. Pribill, I; Speiser, P; Leary, J; Leodolter, S; Hacker, NF; Friedlander, ML; Birnbaum, D; Zeillinger, R; Krainer, M
      High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma

      CANCER GENETICS AND CYTOGENETICS
    3. Obermair, A; Schmid, BC; Stimpfl, M; Fasching, B; Preyer, O; Leodolter, S; Crandon, AJ; Zeillinger, R
      Novel MUC1 splice variants are expressed in cervical carcinoma

      GYNECOLOGIC ONCOLOGY
    4. Tong, D; Fabjani, G; Heinze, G; Obermair, A; Leodolter, S; Zeillinger, R
      Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients

      INTERNATIONAL JOURNAL OF CANCER
    5. Mayerhofer, K; Bodner, K; Bodner-Adler, B; Schindl, M; Kaider, A; Hefler, L; Zeillinger, R; Leodolter, S; Joura, EA; Kainz, C
      Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy

      CANCER
    6. Concin, N; Zeillinger, C; Stimpfel, M; Schiebel, I; Tong, D; Wolff, U; Reiner, A; Leodolter, S; Zeillinger, R
      p53-dependent radioresistance in ovarian carcinoma cell lines

      CANCER LETTERS
    7. Kucera, E; Tong, D; Reinthaller, A; Leodolter, S; Zeillinger, R; Sliutz, G
      p53 polymorphism at codon 72 - does it constitute a risk for squamous intraepithelial lesions and invasive cancer of the cervix in Central Europeans?

      WIENER KLINISCHE WOCHENSCHRIFT
    8. Tong, D; Kucera, E; Schuster, E; Schmutzler, RK; Swoboda, H; Reinthaller, A; Leodolter, S; Zeillinger, R
      Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors

      INTERNATIONAL JOURNAL OF CANCER
    9. Tong, D; Kucera, E; Stimpfl, M; Kolbl, H; Leodolter, S; Zeillinger, R
      Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates

      CLINICAL CHEMISTRY
    10. Tong, D; Schneeberger, C; Czerwenka, K; Schmutzler, RK; Speiser, P; Kucera, E; Concin, N; Kubista, E; Leodolter, S; Zeillinger, R
      Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer

      CLINICAL CANCER RESEARCH
    11. Stimpfl, M; Schmid, BC; Obermair, A; Tong, D; Schiebel, I; Gitsch, G; Leodolter, S; Zeillinger, R
      Comparison of flow cytometry and RT-PCR for the detection of ovarian cancer cells in peripheral blood

      ONCOLOGY RESEARCH
    12. Kucera, E; Speiser, P; Gnant, M; Szabo, L; Samonigg, H; Hausmaninger, H; Mittlbock, M; Fridrik, M; Seifert, M; Kubista, E; Reiner, A; Zeillinger, R; Jakesz, R
      Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients

      EUROPEAN JOURNAL OF CANCER
    13. Stimpfl, M; Schmid, BC; Schiebel, I; Tong, D; Leodolter, S; Obermair, A; Zeillinger, R
      Expression of mucins and cytokeratins in ovarian cancer cell lines

      CANCER LETTERS
    14. Mayerhofer, K; Hefler, L; Schindl, M; Concin, N; Frischmuth, K; Leodolter, S; Zeillinger, R; Reinthaller, A; Kainz, C
      p53 antibody response in patients with vulvar cancer

      ANTICANCER RESEARCH
    15. Mayerhofer, K; Tempfer, C; Kucera, E; Hefler, L; Zeisler, H; Kainz, C; Zeillinger, R; Sliutz, G
      Humoral p53 antibody response is a prognostic parameter in ovarian cancer

      ANTICANCER RESEARCH
    16. Tong, D; Czerwenka, K; Sedlak, J; Schneeberger, C; Schiebel, I; Concin, N; Leodolter, S; Zeillinger, R
      Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines

      BREAST CANCER RESEARCH AND TREATMENT
    17. Tong, D; Stimpfl, M; Reinthaller, A; Vavra, N; Mullauer-Ertl, S; Leodolter, S; Zeillinger, R
      BRCAI gene mutations in sporadic ovarian carcinomas: Detection by PCR and reverse allele-specific oligonucleotide hybridization

      CLINICAL CHEMISTRY
    18. SCHNEEBERGER C; EDER S; SWOBODA H; ULLRICH R; ZEILLINGER R
      A DIFFERENTIAL PCR SYSTEM FOR THE DETERMINATION OF CCND1 (CYCLIN D1) GENE AMPLIFICATION IN HEAD AND NECK SQUAMOUS-CELL CARCINOMAS

      Oral Oncology
    19. Bautista, S; Valles, H; Walker, RL; Anzick, S; Zeillinger, R; Meltzer, P; Theillet, C
      In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity

      CLINICAL CANCER RESEARCH
    20. ADELAIDE J; CHAFFANET M; IMBERT A; ALLIONE F; GENEIX J; POPOVICI C; VANALEWIJK D; TRAPMAN J; ZEILLINGER R; BORRESENDALE AL; LIDEREAU R; BIRNBAUM D; PEBUSQUE MJ
      CHROMOSOME REGION 8P11-P21 - REFINED MAPPING AND MOLECULAR ALTERATIONS IN BREAST-CANCER

      Genes, chromosomes & cancer
    21. KUCERA E; MAYERHOFER K; SEIFERT M; KAINZ C; SLIUTZ G; ZEILLINGER R
      PROGNOSTIC-SIGNIFICANCE OF P53 MUTATIONS IN THE ZINC-BINDING DOMAINS (L2 L3) IN LYMPH NODE-POSITIVE BREAST-CANCER PATIENTS/

      European journal of cancer
    22. TONG D; SCHNEEBERGER C; CZERWENKA K; SCHMUTZLER RK; KUCERA E; KAINZ C; SEIFERT M; ZEILLINGER R; SLIUTZ G
      MESSENGER-RNA DETERMINATION OF ESTROGEN-RECEPTOR, PROGESTIN RECEPTOR,PS2 - PAI-1 BY COMPETITIVE REVERSE TRANSCRIPTION PCR IN HUMAN BREAST-CANCER

      European journal of cancer
    23. JASINSKA J; ZEILLINGER R; HOFFMANNSOMMERGRUBER K; SCHEINER O; WILTSCHKE C; ZIELINSKI CC
      ANTI-HER2 NEU-ANTIBODY BINDING PROFILE IN PATIENTS WITH BREAST-CANCER/

      European journal of cancer
    24. Jasinska, J; Wiltschke, C; Brodowicz, T; Zielinski, CC; Hoffmann-Sommergruber, K; Zeillinger, R
      Anti-HER-2/neu antibodies detected in sera of patients with breast cancer,but also in healthy females

      EUROPEAN JOURNAL OF CANCER
    25. OBERMAIR A; SPEISER P; REISENBERGER K; ULLRICH R; CZERWENKA K; KAIDER A; ZEILLINGER R; MIKSCHE M
      INFLUENCE OF INTRATUMORAL BASIC FIBROBLAST-GROWTH-FACTOR CONCENTRATION ON SURVIVAL IN OVARIAN-CANCER PATIENTS

      Cancer letters
    26. SEDLAK J; HUNAKOVA L; CHORVATH M; SULIKOVA M; NOVOTNY L; BOLJESIKOVA E; ZEILLINGER R; CHORVATH B
      RESISTANCE OF HUMAN MULTIDRUG-RESISTANT NEOPLASTIC CELL-LINES TO PACLITAXEL-INDUCED-RADIOSENSITIZATION IS REDUCED BY THE NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOG SDZ PSC-833

      Anticancer research
    27. HEFLER L; TEMPFER C; HEUSLER G; KUCERA E; MAYERHOFER K; ZEILLINGER R; REINTHALLER A; KAINZ C
      CYTOSOL CONCENTRATIONS OF CD44 ISOFORMS IN BREAST-CANCER TISSUE

      International journal of cancer
    28. Obermair, A; Tempfer, C; Hefler, L; Preyer, O; Kaider, A; Zeillinger, R; Leodolter, S; Kainz, C
      Concentration of vascular endothelial growth factor (VEGF) in the serum ofpatients with suspected ovarian cancer

      BRITISH JOURNAL OF CANCER
    29. TSCHUGGUEL W; ZHEGU Z; SCHNEEBERGER C; TANTSCHER E; CZERWENKA K; FABRY A; WOJTA J; ZEILLINGER R; HUBER JC
      ESTROGEN DOES NOT INDUCE THE CALCIUM-DEPENDENT NITRIC-OXIDE SYNTHASE IN CULTURED HUMAN UTERINE ENDOTHELIAL AND MYOMETRIAL SMOOTH-MUSCLE CELLS

      Journal of vascular research
    30. SLIUTZ G; TEMPFER C; HANZAL E; REINTHALLER A; KOELBL H; ZEILLINGER R; KAINZ C
      SERUM M3 M21 IN CERVICAL-CANCER PATIENTS

      European journal of cancer
    31. KUCERA E; KAINZ C; TEMPFER C; ZEILLINGER R; KOELBL H; SLIUTZ G
      PROSTATE-SPECIFIC ANTIGEN (PSA) IN BREAST AND OVARIAN-CANCER

      Anticancer research
    32. FISCHERCOLBRIE J; WITT A; HEINZL H; SPEISER P; CZERWENKA K; SEVELDA P; ZEILLINGER R
      EGFR AND STEROID-RECEPTORS IN OVARIAN-CARCINOMA - COMPARISON WITH PROGNOSTIC PARAMETERS AND OUTCOME OF PATIENTS

      Anticancer research
    33. SPEISER P; MAYERHOFER K; KUCERA E; ROCH G; MITTELBOCK M; GITSCH G; ZEILLINGER R
      PS2 AND PAI-1 IN OVARIAN-CANCER - CORRELATION TO PATHOHISTOLOGICAL PARAMETERS

      Anticancer research
    34. SLIUTZ G; SCHMIDT W; TEMPFER C; SPEISER P; GITSCH G; EDER S; SCHNEEBERGER C; KAINZ C; ZEILLINGER R
      DETECTION OF P53 POINT MUTATIONS IN PRIMARY HUMAN VULVAR CANCER BY PCR AND TEMPERATURE-GRADIENT GEL-ELECTROPHORESIS

      Gynecologic oncology
    35. KRAINER M; BRODOWICZ T; ZEILLINGER R; WILTSCHKE C; SCHOLTEN C; SEIFERT M; KUBISTA E; ZIELINSKI CC
      TISSUE EXPRESSION AND SERUM LEVELS OF HER-2 NEU IN PATIENTS WITH BREAST-CANCER/

      Oncology
    36. OBERMAIR A; KUCERA E; MAYERHOFER K; SPEISER P; SEIFERT M; CZERWENKA K; KAIDER A; LEODOLTER S; KAINZ C; ZEILLINGER R
      VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) IN HUMAN BREAST-CANCER - CORRELATION WITH DISEASE-FREE SURVIVAL

      International journal of cancer
    37. SCHMUTZLER RK; BIERHOFF E; WERKHAUSEN T; FIMMERS R; SPEISER P; KUBISTA E; KREBS D; ZEILLINGER R; WIESTLER OD; VONDEIMLING A
      GENOMIC DELETIONS IN THE BRCA1, BRCA2 AND TP53 REGIONS ASSOCIATE WITHLOW EXPRESSION OF THE ESTROGEN-RECEPTOR IN SPORADIC BREAST-CARCINOMA

      International journal of cancer
    38. ZEILLINGER R; TONG DCC; VAVRA N; LEODOLTER S
      SIMULTANEOUS DETECTION OF FREQUENT BRCA1 MUTATIONS BY REVERSE HYBRIDIZATION ON MEMBRANE STRIPS

      Clinical chemistry
    39. COURJAL F; CUNY M; SIMONYLAFONTAINE J; LOUASON G; SPEISER P; ZEILLINGER R; RODRIGUEZ C; THEILLET C
      MAPPING OF DNA AMPLIFICATIONS AT 15 CHROMOSOMAL LOCALIZATIONS IN 1875BREAST-TUMORS - DEFINITION OF PHENOTYPIC GROUPS

      Cancer research
    40. TONG D; SCHNEEBERGER C; LEODOLTER S; ZEILLINGER R
      QUANTITATIVE-DETERMINATION OF GENE-EXPRESSION BY COMPETITIVE REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION IN DEGRADED RNA SAMPLES

      Analytical biochemistry
    41. SCHNEEBERGER C; ZEILLINGER R
      PCR-MEDIATED SYNTHESIS OF EXOGENOUS COMPETITORS FOR QUANTITATIVE RT-PCR

      BioTechniques
    42. TEMPFER C; HANZAL E; ZEILLINGER R; KOELBL H; DADAK CH; KAINZ CH
      THE SERUM TUMOR-MARKER M3 M21 IN THE FOLLOW-UP OF BREAST-CANCER PATIENTS/

      Anticancer research
    43. ZEILLINGER R; EDER S; SCHNEEBERGER C; ULLRICH R; SPEISER P; SWOBODA H
      CATHEPSIN-D AND PAI-1 EXPRESSION IN HUMAN HEAD AND NECK-CANCER

      Anticancer research
    44. SPEISER P; GHAREHBAGHISCHNELL E; SCHNEEBERGER C; EDER S; ZEILLINGER R
      MICRODISSECTION AS A MEANS TO VERIFY ALLELIC IMBALANCE IN TUMOR BIOLOGY SAMPLES

      Anticancer research
    45. SLIUTZ G; EDER H; KOELBL H; TEMPFER C; AUERBACH L; SCHNEEBERGER C; KAINZ C; ZEILLINGER R
      QUANTIFICATION OF UPA RECEPTOR EXPRESSION IN HUMAN BREAST-CANCER CELL-LINES BY CRT-PCR

      Breast cancer research and treatment
    46. ZEILLINGER R; TANTSCHER E; SCHNEEBERGER C; TSCHUGGUEL W; EDER S; SLIUTZ G; HUBER JC
      SIMULTANEOUS EXPRESSION OF NITRIC-OXIDE SYNTHASE AND ESTROGEN-RECEPTOR IN HUMAN BREAST-CANCER CELL-LINES

      Breast cancer research and treatment
    47. COURJAL F; LOUASON G; SPEISER P; KATSAROS D; ZEILLINGER R; THEILLET C
      CYCLIN GENE AMPLIFICATION AND OVEREXPRESSION IN BREAST AND OVARIAN CANCERS - EVIDENCE FOR THE SELECTION OF CYCLIN D1 IN BREAST AND CYCLIN-EIN OVARIAN-TUMORS

      International journal of cancer
    48. SCHMUTZLER RK; FIMMERS R; BIERHOFF E; LOHMAR B; HOMANN A; SPEISER P; KUBISTA E; JAEGER K; KREBS D; ZEILLINGER R; WIESTLER OD; VONDEIMLING A
      ASSOCIATION OF ALLELIC LOSSES ON HUMAN CHROMOSOMAL ARMS 11Q AND 16Q IN SPORADIC BREAST-CANCER

      International journal of cancer
    49. MAYERHOFER K; STOLZLECHNER J; YILDIZ S; HAIDER K; HEINZL H; JAKESZ R; PECHERSTORFER M; ROSEN H; SEVELDA P; ZEILLINGER R; SPEISER P
      PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND PRO GNOSIS IN CARCINOMA OF THE BREAST

      Geburtshilfe und Frauenheilkunde
    50. TSCHUGGUEL W; KNOGLER W; CZERWENKA K; MILDNER M; WENINGER W; ZEILLINGER R; HUBER JC
      PRESENCE OF ENDOTHELIAL CALCIUM-DEPENDENT NITRIC-OXIDE SYNTHASE IN BREAST APOCRINE METAPLASIA

      British Journal of Cancer
    51. SPEISER P; GHAREHBAGHISCHNELL E; EDER S; HAID A; KOVARIK J; NENUTIL R; SAUTER G; SCHNEEBERGER CH; VOJTESEK B; WILTSCHKE CH; ZEILLINGER R
      A CONSTITUTIONAL DE-NOVO MUTATION IN EXON-8 OF THE P53 GENE IN A PATIENT WITH MULTIPLE PRIMARY MALIGNANCIES

      British Journal of Cancer
    52. COURJAL F; CUNY M; RODRIGUEZ C; LOUASON G; SPEISER P; KATSAROS D; TANNER MM; ZEILLINGER R; THEILLET C
      DNA AMPLIFICATIONS 20Q13 AND MDM2 DEFINE DISTINCT SUBSETS OF EVOLVED BREAST AND OVARIAN-TUMORS

      British Journal of Cancer
    53. SCHNEEBERGER C; SPEISER P; KURY F; ZEILLINGER R
      QUANTITATIVE DETECTION OF REVERSE TRANSCRIPTASE-PCR PRODUCTS BY MEANSOF A NOVEL AND SENSITIVE DNA STAIN

      PCR methods and applications
    54. OBERKANINS C; GEURTSMOESPOT A; ZEILLINGER R; KURY F; LEAKE RE; BENRAAD TJ
      THE PERFORMANCE OF A COMMERCIAL RADIOLIGAND BINDING ASSAY FOR THE EPIDERMAL GROWTH-FACTOR RECEPTOR IS COMPARABLE TO THE EORTC STANDARD ASSAY

      European journal of cancer
    55. BRODOWICZ T; KRAINER M; ZEILLINGER R; BUDINSKY AC; WILTSCHKE C; ZIELINSKI CC
      TISSUE EXPRESSION AND SERUM LEVELS OF HER-2 NEU IN PATIENTS WITH BREAST-CANCER/

      European journal of cancer
    56. WILTSCHKE C; KRAINER M; BUDINSKY AC; BERGER A; MULLER C; ZEILLINGER R; SPEISER P; KUBISTA E; EIBL M; ZIELINSKI CC
      REDUCED MITOGENIC STIMULATION OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS AS A PROGNOSTIC PARAMETER FOR THE COURSE OF BREAST-CANCER - A PROSPECTIVE LONGITUDINAL-STUDY

      British Journal of Cancer
    57. AHNER R; EGARTER C; KISS H; HEINZL K; ZEILLINGER R; SCHATTEN C; DORMEIER A; HUSSLEIN P
      FETAL FIBRONECTIN AS A SELECTION CRITERION FOR INDUCTION OF TERM LABOR

      American journal of obstetrics and gynecology
    58. AHNER R; KISS H; EGARTER C; ZEILLINGER R; EPPEL W; KARAS H; HUSSLEIN P
      FETAL FIBRONECTIN AS A MARKER TO PREDICT THE ONSET OF TERM LABOR AND DELIVERY

      American journal of obstetrics and gynecology
    59. KARLSEDER J; ZEILLINGER R; SCHNEEBERGER C; CZERWENKA K; SPEISER P; KUBISTA E; BIRNBAUM D; GAUDRAY P; THEILLET C
      PATTERNS OF DNA AMPLIFICATION AT BAND-Q13 OF CHROMOSOME-11 IN HUMAN BREAST-CANCER

      Genes, chromosomes & cancer
    60. KIRCHWEGER R; ZEILLINGER R; SCHNEEBERGER C; SPEISER P; LOUASON G; THEILLET C
      PATTERNS OF ALLELE LOSSES SUGGEST THE EXISTENCE OF 5 DISTINCT REGIONSOF LOH ON CHROMOSOME-17 IN BREAST-CANCER

      International journal of cancer
    61. WILTSCHKE C; TYL E; SPEISER P; STEININGER A; ZEILLINGER R; KURY F; CZERWENKA K; KUBISTA E; PREIS P; KRAINER M; ZIELINSKI CC
      INCREASED NATURAL-KILLER-CELL ACTIVITY CORRELATES WITH LOW OR NEGATIVE EXPRESSION OF THE HER-2 NEU ONCOGENE IN PATIENTS WITH BREAST-CANCER/

      Cancer
    62. ZEILLINGER R; SCHNEEBERGER C; SPEISER P; KURY F
      RAPID QUANTITATIVE-ANALYSIS OF DIFFERENTIAL PCR PRODUCTS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      BioTechniques
    63. SPEISER P; ZEILLINGER R; WILTSCHKE C; SEDLAK J; CHORVATH B
      IL-1-ALPHA-INDUCED, TNF-ALPHA-MEDIATED HLA CLASS-II (DR) ANTIGEN UP-REGULATION IN A HUMAN DUCTAL BREAST-CARCINOMA CELL-LINE ZR-75-1

      Neoplasma
    64. SLIUTZ G; SPEISER P; SCHULTZ AM; SPONA J; ZEILLINGER R
      AGNUS-CASTUS EXTRACTS INHIBIT PROLACTIN SECRETION OF RAT PITUITARY-CELLS

      Hormone and Metabolic Research
    65. ZEILLINGER R; KURY F; SPEISER P; SLIUTZ G; CZERWENKA K; KUBISTA E
      EGF-R AND STEROID-RECEPTORS IN BREAST-CANCER - A COMPARISON WITH TUMOR GRADING, TUMOR SIZE, LYMPH-NODE INVOLVEMENT, AND AGE

      Clinical biochemistry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 13:21:00